Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

2.43
-0.0300-1.22%
Post-market: 2.430.00000.00%16:10 EDT
Volume:25.12K
Turnover:61.47K
Market Cap:4.46M
PE:-0.09
High:2.52
Open:2.42
Low:2.41
Close:2.46
52wk High:36.65
52wk Low:1.50
Shares:1.84M
Float Shares:1.65M
Volume Ratio:0.04
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.1846
EPS(LYR):-63.7804
ROE:-151.36%
ROA:-13.88%
PB:0.60
PE(LYR):-0.04

Loading ...

Dawson Geophysical (DWSN) Stock Surges Over 16% Overnight: Why Is It Moving?

Benzinga Earnings
·
May 15

HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session

Benzinga Earnings
·
May 15

HCW Biologics swings to Q1 profit of $3.47 million; revenue rises to $6.54 million

Reuters
·
May 15

HCW Biologics Q1 revenue surges on licensing deal

Reuters
·
May 15

HCW Biologics Q1 EPS $0.37 Beats $(0.44) Estimate, Sales $6.543M Up From $5.065K YoY

Benzinga Earnings
·
May 15

HCW Biologics: on Track to Report Phase 1 HCW9302 Alopecia Data in H1 2026

THOMSON REUTERS
·
May 15

HCW Biologics, Inc Q1 Basic EPS USD 0.37

THOMSON REUTERS
·
May 15

Press Release: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

Dow Jones
·
May 15

HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia

TIPRANKS
·
May 14

BRIEF-HCW Biologics Discovers That HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies

Reuters
·
May 14

HCW Biologics Inc - Expects to Complete Ind-Enabling Studies in H2 2027 and File Ind Application for HCW11-040

THOMSON REUTERS
·
May 14

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

GlobeNewswire
·
May 14

HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

GlobeNewswire
·
May 01

HCW Biologics Inc - Agreement to Commence on or About May 1, 2026, Subject to Public Offering Close - SEC Filing

THOMSON REUTERS
·
Apr 30

HCW Biologics Inc - on April 25, Co to Enter $2.5 Mln Marketing Consulting Agreement With I.r. Agency Llc - SEC Filing

THOMSON REUTERS
·
Apr 30

HCW Biologics to file IND for HCW11-018b in first half of 2027

TIPRANKS
·
Apr 27

BRIEF-Hcw Biologics Delivers A Major Update For Its T-Cell Engager Program Revealing Mechanism Of Action

Reuters
·
Apr 27

HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors

GlobeNewswire
·
Apr 27

HCW Biologics Lowers Shareholder Meeting Quorum Requirement

TIPRANKS
·
Apr 17

HCW Biologics lowers shareholder meeting quorum to 33.3% voting power

Reuters
·
Apr 17